|Articles|December 5, 2014
Innocutis has launched its newest product, Sitavig
Advertisement
INNOCUTIS has launched its newest product, Sitavig (acyclovir) 50 mg buccal tablets. Sitavig uses Lauriad technology, which consists of a tablet that sticks to the gum, above the canine tooth on the side of the lip that is infected with a cold sore, according to the company. This white- to slightlyyellow tablet is tasteless and odorless. It dissolves to provide a sustained release of medicine.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
The “6-7” Advances for Dermatologists to Look Forward to in 2026
2
Lebrikizumab Enters Late-Stage Testing for Nummular Eczema
3
Clinicians See Intersection of Weight Loss and Facial Aging
4
Top 5 Articles of the Week: January 11-16
5














